© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
September 22, 2021
An oncologist discusses the future of myelodysplastic syndrome, including upcoming studies and potential treatments.
Dr. Naval Daver provides insight on the emerging first-line treatment options for high-risk myelodysplastic syndrome and breaks down clinical trial data.
An expert details the treatment options for high-risk myelodysplastic syndrome.
Naval Daver, MD, illustrates the goals of treatment and treatment options for low-risk myelodysplastic syndrome.
A key opinion leader describes how myelodysplastic syndrome is diagnosed, the typical presenting symptoms, and the methods of risk assessment.
Naval Daver, MD, explains myelodysplastic syndrome, including risk factors and potential complications.